Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)

National Institutes of Health

Funding

Estimated total program funding: $5,500,000

About

The purpose of this notice of funding opportunity (NOFO) is to elucidate the key components of the therapeutic effects of rapid-acting psychotropic interventional drugs (RAPIDs) by addressing the methodological challenges involved with these clinical trials. In addition, this NOFO seeks to advance understanding of how RAPIDs and adjunctive psychosocial interventions can be optimally delivered, monitored, and sustained over time to enhance effectiveness and generalizability. The NOFO will support studies designed to enhance the rigor of RAPID clinical trial design, which will ultimately increase the interpretability of the data and the generalizability of the results.

Eligibility

Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Applicant types

Grants.gov eligibility code 00 Grants.gov eligibility code 01 Grants.gov eligibility code 02 Grants.gov eligibility code 04 Grants.gov eligibility code 05 Grants.gov eligibility code 06 Grants.gov eligibility code 07 Grants.gov eligibility code 08 Grants.gov eligibility code 11 Grants.gov eligibility code 12 Grants.gov eligibility code 13 Grants.gov eligibility code 20 Grants.gov eligibility code 22 Grants.gov eligibility code 23 Grants.gov eligibility code 25

Visit Official Funding Page →

Continue researching

Related current grants

All Health & Medical grants →

Ending HIV and TB as public health threats through an accelerated and sustained comprehensive response in India

Centers for Disease Control-GHC

The Award Ceiling for Year 1 is 0 (none). CDC anticipates an Approximate Total Fiscal Year Funding amount of $6,000,000 for Year 1, subject to the availability of funds.This NOFO supports India"s National AIDS Control Organization (NACO), Central Tuberculosis Division (CTD), and other departmen

Trauma Care Readiness and Coordination Cooperative Agreement

Assistant Secretary for Preparedness and Response

A trauma system is, “…an organized, inclusive approach to facilitating and coordinating a multidisciplinary system response to severely injured patients.”[14] Coordination across prehospital entities (e.g., EMS) and hospitals signal an effective trauma system, where patients can ge

NCI Community Oncology Research Program (NCORP) Academic Community Sites (UG1 Clinical Trials Not Allowed)

National Institutes of Health

This Notice of Funding Opportunity (NOFO) is one of three NOFOs for the National Cancer Institute (NCI) Community Oncology Research Program (NCORP). NCORP is designed to enhance generalizability and dissemination of clinical trial and other human subject research study results through accrual in a v

NCI Community Oncology Research Program (NCORP) Research Bases (UG1 Clinical Trial Required)

National Institutes of Health

Notice-specific evidence check

What an applicant must verify for Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)

Applicant evidence

Applicant type: State governments
Applicant type: County governments
Applicant type: City or township governments
Applicant type: Special district governments
Applicant type: Independent school districts
Applicant type: Public and state-controlled institutions of higher education
Applicant type: Federally recognized tribal governments
Applicant type: Public housing authorities and Indian housing authorities

Opportunity boundaries

Recorded funding: Estimated total program funding: $5,500,000
Recorded deadline: October 12, 2026; confirm time zone and submission system.
Recorded focus: Health

Before investing in an application, connect every eligibility claim, required registration, submission component and deadline to the current official notice. Open the recorded official source →

Application checklist

How to apply for Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Interventional Drugs (RAPIDs) (R01 Clinical Trial Required)

The steps below turn the recorded grant fields into a pre-submission check. They do not replace the current Notice of Funding Opportunity or its amendments.

Recorded eligibility

• Applicant types: Grants.gov eligibility code 00, Grants.gov eligibility code 01, Grants.gov eligibility code 02, Grants.gov eligibility code 04, Grants.gov eligibility code 05, Grants.gov eligibility code 06.
• Geographic scope is not structured in this record.
• Notice summary: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.

Focus areas: HL

Recorded deadline

October 11, 2026 — confirm the time zone and submission system

A missing or rolling date is not permission to assume an open application window.

1. Confirm fitMatch your applicant type, location, project scope and any cost-share or registration rule to the official notice.
2. Read the noticeCollect the current guidelines, amendments, budget rules, required attachments and submission instructions.
3. Check timingRecord the deadline time zone, internal review date and any earlier registration or portal cut-off.
4. Submit thereUse the official application route and save the confirmation or submission reference.

Official sources

Recorded source: https://www.grants.gov/xml-extract

Open official notice →

Last directory verification: Sep 13, 2026.